TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00496457

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: 4 Capsules of PBO per day before noon meal
Study: NCT04204980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab dose escalation
Description: - Step I: dose-escalation 3 patients treated weekly during four weeks with 4 mg/kg of daratumumab, then 3 patients treated weekly during four weeks with 8 mg/kg of daratumumab, then 3 patients treated weekly four weeks with 16 mg/kg of daratumumab
Study: NCT02426710

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intracardiac echocardiography
Description: Flutter ablation will be done using intracardiac echocardiography.
Study: NCT00004160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study: NCT02426710

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intracardiac echocardiography
Description: Flutter ablation will be done using intracardiac echocardiography.
Study: NCT00004160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study: NCT02666300

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TaperGuard ETT
Description: tracheal intubation with TaperGuard ETT
Study: NCT00527657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: Starting dose 30 mg/m\^2 by mouth daily on Day 1 and 29.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 75 mg/m\^2 by mouth daily on Days 1 to 42.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: 200 mg/m\^2 by mouth daily.
Study: NCT01933373

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Toupet
Description: Laparoscopic posterior partial fundoplication plus myotomy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dor
Description: Anterior partial fundoplication plus myotomy.
Study: NCT02713022

Intervention type: DEVICE
Intervention: DEXA Scan

Intervention type: DEVICE
Intervention: DEXA Scan

Intervention type: BEHAVIORAL
Intervention: Godin Leisure Time Exercise Questionnaire (GLTEQ)

Intervention type: BEHAVIORAL
Intervention: Godin Leisure Time Exercise Questionnaire (GLTEQ)
Study: NCT02817841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15 mg E4/3 mg DRSP
Description: 15 mg estetrol and 3 mg drospirenone tablets administered once daily for 13 consecutive cycles following a 24/4-day regimen, i.e. one 15 mg E4/3 mg DRSP active tablet per day for 24 consecutive days followed by one placebo tablet per day for 4 consecutive days.
Study: NCT00004160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study: NCT04204980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab full dose
Description: - Step II: expansion cohort to 13 patients (with 10 new patients included and the last 3 patients from the step I) with eight weekly doses of 16 mg/kg daratumumab
Study: NCT01109862

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total hip arthroplasty
Description: All cemented THA

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemiarthroplasty
Description: Cemented bipolar HAP
Study: NCT02109354

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ALVAC-HIV
Description: Formulated as a lyophilized vaccine for injection and is reconstituted with 1.05 mL of sterile Sodium Chloride solution (0.4% NaCl) for a single 1 mL dose of \>1.0 x 106 CCID50/mL, to administer intramuscularly (IM).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ALVAC-HIV
Description: Formulated as a lyophilized vaccine for injection and is reconstituted with 1.05 mL of sterile Sodium Chloride solution (0.4% NaCl) for a single 1 mL dose of \>1.0 x 106 CCID50/mL, to administer intramuscularly (IM).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AIDSVAX B/E
Description: 300 mcg of subtype B (MN) HIV gp120 glycoprotein and 300 mcg of subtype E (A244) HIV gp120 glycoprotein adsorbed onto 600 mcg of aluminum hydroxide gel adjuvant. Each vial contains 1.2 mL of sterile suspension, to administer 1 mL IM.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AIDSVAX B/E
Description: 300 mcg of subtype B (MN) HIV gp120 glycoprotein and 300 mcg of subtype E (A244) HIV gp120 glycoprotein adsorbed onto 600 mcg of aluminum hydroxide gel adjuvant. Each vial contains 1.2 mL of sterile suspension, to administer 1 mL IM.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ALVAC-HIV
Description: A sterile, lyophilized product that consists of a mixture of virus stabilizer, and freeze drying medium and is reconstituted with 1.05 mL of sterile Sodium Chloride (0.4% NaCl) for a single 1 mL dose, to administer IM.
Study: NCT00004160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT04105478

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Shoulder arthroplasty
Description: Patients suffering from severe glenohumeral osteoarthritis are treated surgically by a total shoulder arthroplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Shoulder arthroplasty
Description: Patients suffering from severe glenohumeral osteoarthritis are treated surgically by a total shoulder arthroplasty
Study: NCT00004160

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT02109354

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for AIDSVAX B/E
Description: Sodium Chloride for Injection, 0.9% administered IM.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis B vaccine
Description: Each 1 mL dose contains 20 mcg of hepatitis B surface antigen (HBsAg) adsorbed onto 500 mcg aluminum as aluminum hydroxide, to administer IM.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Hepatitis B vaccine
Description: Each 1 mL dose contains 20 mcg of hepatitis B surface antigen (HBsAg) adsorbed onto 500 mcg aluminum as aluminum hydroxide, to administer IM.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tetanus toxoid vaccine
Description: The active ingredient is tetanus toxoid (≥ 40 I.U. / 0.5 mL) adsorbed on aluminium hydroxide dihydrate (600 mcg of aluminium), to administer IM.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Tetanus toxoid vaccine
Description: The active ingredient is tetanus toxoid (≥ 40 I.U. / 0.5 mL) adsorbed on aluminium hydroxide dihydrate (600 mcg of aluminium), to administer IM.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for hepatitis B vaccine
Description: Sodium Chloride for Injection, 0.9% administered IM.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for tetanus vaccine
Description: Sodium Chloride for Injection, 0.9% administered IM.
Study: NCT00783861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactic Acid
Description: Lactic Acid (Dermacyd Femina)
Study: NCT03232372

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: External-Connection non-submerged Imp
Description: Through a surgical procedure, we will implant implant whit external connection and non submerged to patients.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Internal Connection Submerged implants
Description: Through a surgical procedure, we will implant implant whit internal connection and submerged to patients.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Internal Connection non-Submerged Impl
Description: Through a surgical procedure, we will implant implant whit internal connection and non-submerged to patients.
Study: NCT00398515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01677962

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Poly-ICLC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dendritic cell
Study: NCT04758260

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Antioxidant
Description: Oral antioxidant oral intake in the 3 months prior to inclusion in the study
Study: NCT01386294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir gel
Description: Tenofovir gel is a clear, transparent, viscous gel at concentrations of 1% formulated in purified water with edentate disodium, citric acid, glycerin, methylparaben, propylparaben, HEC, and pH adjusted to 4-5. Tenofovir gel will be supplies in a 4 ml single use applicator containing approximately 4 grams of gel, equivalent to approximately 40mg of tenofovir.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Universal placebo gel
Description: The placebo gel is an inert gel containing HEC as the gelling agent, purified water, sodium chloride, sorbic acid and sodium hydroxide. Each applicator contains approximately 4ml of placebo gel
Study: NCT00406068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycobacterial cell wall-DNA complex
Description: 8 mg MCC, intravesical - Induction Phase (6 weekly intravesical instillations) and Maintenance Phase (3 weekly instillations at months 3, 6, 12, 18 and 24).
Study: NCT05352087

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic cholecystectomy
Description: Laparoscopic cholecystectomy is minimally invasive surgery to remove the gallbladder.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic cholecystectomy
Description: Laparoscopic cholecystectomy is minimally invasive surgery to remove the gallbladder.
Study: NCT01049334

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants were instructed to suck one placebo lozenge during the initial two-hour clinic visit. Upon discharge, participants were instructed to use study medication lozenge every 3-6 hours as needed for pain, up to a total of 5 study lozenges in 24 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Description: Participants were instructed to suck one flurbiprofen 8.75 mg lozenge during the initial two-hour clinic visit. Upon discharge, participants were instructed to use study medication lozenge every 3-6 hours as needed for pain, up to a total of 5 study lozenges in 24 hours.
Study: NCT01722474

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ASI Device
Study: NCT03084822

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FAITH! App digital intervention
Description: The digital app will include 10 education modules addressing the major CVD risk factors to be delivered on-demand through an innovative, interactive video series. The digital app will also support the multi-media education modules, interactive surveys/quizzes, self-monitoring (diet, physical activity), and social networking (discussion board) functionality.
Study: NCT02326610

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human growth hormone,ZOMACTON® (somatropin)
Description: The initial dose will be 30µg/kg/day. The maximal dose will be 40µg/kg/day. The dose will be adjusted by monitoring the serum IGF-I level. Growth hormone will be delivered by injection.
Study: NCT02932696

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac training program
Description: This program takes place at the Cardiovascular Rehabilitation Department at the Nîmes University Hospital and includes a combination of various physical activities: treadmill, exercise bike, rower, aerobics, gymnastics, serious games, swimming. The program begins approximately within 3 months after myocardial infarction and consists of 20 consecutive days of training. The main physical activity is aerobic interval training (AIT).~30-minute AIT sessions will occur 5x per week for 4 weeks.~1 AIT session includes a warm up for 8 minutes to reach a heart rate during exercise corresponding to 20 to 30% of maximum aerobic power determined during the initial effort test. Then interval training occurs with 4x2 min of high intensity effort (heart rate during exercise corresponding to 80% of maximum aerobic power) alternating with 2 min of active recovery at 20-30% of maximum aerobic power. Then recovery for 8 minutes.
Study: NCT02125370

Intervention type: OTHER
Intervention: Qualitative and survey
Study: NCT03744715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poziotinib
Description: Poziotinib
Study: NCT01423760

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tecemotide
Description: Subjects who received tecemotide (L-BLP25) for the treatment of non-small cell lung cancer (NSCLC) or multiple myeloma in a feeder trial will continue to be treated with tecemotide (L-BLP25) and have safety assessments performed until the discontinuation criteria in the respective feeder trial protocol are met.

Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: Subjects who had not received tecemotide in the feeder study, or who had discontinued treatment with tecemotide (L-BLP25), will only be observed for progressive disease (PD) (if applicable) and survival in 6-month intervals and will not be provided treatment with tecemotide (L-BLP25).
Study: NCT01726205

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin and normal saline infusion, PRG
Study: NCT01375075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2484595
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2484595
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2484595
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2484595
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Administered orally
Study: NCT02901665

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FCC intervention
Description: Communication to all NICU families that they should be in the NICU a minimum of 4 hours/day.
Study: NCT03417401

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vitrectomy with retinal vein cannulation and intravenous rtPA (Actilyse) infusion up to 1mg.
Description: Standard 3-port pars plana vitrectomy with surgical stabilizer assisted ( surgical robot) retinal vein cannulation with recombinant tissue Plasminogen Activator (Actilyse-0.25mg/ml) infusion with a maximal dose of 1mg..

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Infusion
Description: Intravenous infusion in a retinal vein with rtPA (Actilyse 0.25mg/ml).
Study: NCT02101697

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV Stigma Reduction Intervention
Description: The HIV stigma reduction intervention consists of two computer-administered sessions and one group session.~Session 1. (approx. 60 min). Introduction of the concepts of stigma and discrimination, vulnerable populations and symbolic stigma delivered in an interactive tablet format, using games and videos.~Session 2. (approx. 60 min). Interactive activities to address HIV transmission myths and misconceptions and the importance of universal precautions.~Session 3. (approx 90 min). Patient interaction skills. In person interactive group session co-facilitated by PLHIV and staff focusing on skills building through role-plays and feedback.~Our previous research has found that these modules address factors identified as contributing to health professionals' stigma.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: HIV Stigma Reduction Intervention
Description: The HIV stigma reduction intervention consists of two computer-administered sessions and one group session.~Session 1. (approx. 60 min). Introduction of the concepts of stigma and discrimination, vulnerable populations and symbolic stigma delivered in an interactive tablet format, using games and videos.~Session 2. (approx. 60 min). Interactive activities to address HIV transmission myths and misconceptions and the importance of universal precautions.~Session 3. (approx 90 min). Patient interaction skills. In person interactive group session co-facilitated by PLHIV and staff focusing on skills building through role-plays and feedback.~Our previous research has found that these modules address factors identified as contributing to health professionals' stigma.
Study: NCT01726205

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin and ropivacaine 02% infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drug, normal saline infusion
Study: NCT02738723

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: 40 Gy for each patient. Patients receiving once-daily therapy ,4 Gy daily in 10 treatments over a period of two weeks.
Study: NCT04628377

Intervention type: DEVICE
Intervention: Angiography-drived Index of Microcirculatory Resistance
Description: From coronary angiographic images, angiography-derived IMR will be calculated based on mathematical calculation.~Angiography-derived IMR = (hyperemic Pa x angiography-derived FFR) x (vessel length / {K x V diastole}).~Hyperemic Pa will be estimated from resting Pa according to prespecified equation.

Intervention type: DEVICE
Intervention: Angiography-drived Index of Microcirculatory Resistance
Description: From coronary angiographic images, angiography-derived IMR will be calculated based on mathematical calculation.~Angiography-derived IMR = (hyperemic Pa x angiography-derived FFR) x (vessel length / {K x V diastole}).~Hyperemic Pa will be estimated from resting Pa according to prespecified equation.
Study: NCT04049682

Intervention type: BEHAVIORAL
Intervention: Delayed School Start Time
Description: Francis Parker High School implemented 45-minute later school start time.
Study: NCT04411381

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telemedicine
Description: Telemedicine associated with dried blood spot testing at home for RNA test to sustained virological response determination
Study: NCT04392700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate 300mg
Description: Take the medicine once a day ，300mg/d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir 0.5 mg
Description: Take the medicine once a day，0.5 mg/d
Study: NCT01516333

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High GL 107
Description: Three meals a day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medium GL 76
Description: Three meals a day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medium GL 68
Description: Three meals a day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low GL 48
Description: Three meals a day
Study: NCT00004160

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT03498820

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Analgesia Nociception Index
Description: : Non invasive monitor based on heart rate variability analysis, assessing the parasympathetic nervous activity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: intravenous short-acting opioid routinely administered during general anesthesia
Study: NCT04415866

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Paced Auditory Serial Addition task (PASAT)
Description: Single and double digits are presented at intervals between 2 and 3 seconds and the participant must add each new digit to the one immediately prior to it. The participants will be asked to indicate by electronic button press whether the sum of the addition is 13 or not. The duration of the PASAT will be two 12-min tasks.
Study: NCT02738723

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT
Description: 45 Gy for each patient，Accelerated twice-daily thoracic radiotherapy involved the administration of 1.5 Gy in 30 treatments over a period of three weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP
Description: Etoposide 75mg/m2/iv over 90min through day 1 to day 4 and cisplatin 25mg/m2/iv over 30min through day 1 to day 3, repeat Q 3weeks. Continuous administration to six cycles or to disease progression, unacceptable toxicity or patients' refusal.
Study: NCT00538083

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chocolate
Description: 74 grams of single dose solid dark chocolate versus placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chocolate
Description: 22 grams of single dose sugared cocoa, sugar-free cocoa, and placebo
Study: NCT00655928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: N-acetylcysteine 240mg/kg in 1 litre 0.9% saline intravenous over 12 hours pre-operatively

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: 0.9% saline 1 litre intravenous over 12 hours pre-operatively
Study: NCT01904799

Intervention type: OTHER
Group type: OTHER
Intervention: Cognitive Assessment test